Skip to main content
Observe Medical logo

Observe Medical — Investor Relations & Filings

Ticker · OBSRV ISIN · NO0010865009 LEI · 9845005F38B74FFJ1B65 Euronext Expand Manufacturing
Open in API
Filings indexed 643 across all filing types
Latest filing 2024-06-04 Regulatory Filings
Country NO Norway
Listing Euronext Expand OBSRV

About Observe Medical

https://observemedical.com/

Observe Medical is a medical technology company that develops, markets, and sells innovative medtech products for the global market. The company is committed to improving patient welfare and outcomes, increasing clinical data accuracy, and promoting positive health economics. It is building a scalable medtech platform that combines a portfolio of proprietary products with strategic partnerships, leveraging its manufacturing, development, regulatory, and commercial capabilities to bring new technologies to market.

Recent filings

Filing Released Lang Actions
Observe Medical ASA announces Letter of Intent with Sulacare for Female Catheterization Product Launch
Regulatory Filings Classification · 100% confidence The document is a press release announcing that Observe Medical ASA has entered into a Letter of Intent (LOI) with Sulacare AS to collaborate on the commercial launch of a female catheterization product. This announcement details a strategic partnership, future negotiations for a formal agreement, and profit-sharing models. This type of announcement, concerning strategic business development, partnerships, and potential future transactions (like joint marketing/distribution), most closely aligns with the scope of a general regulatory announcement or a filing related to corporate activity that isn't strictly financial reporting (10-K, IR, ER) or insider trading (DIRS). Since it is a specific announcement about a business development/partnership, and there is no specific code for 'Partnership Announcement', it falls best under the general 'Regulatory Filings' (RNS) category, as it is a material event disclosure. It is too specific for a general LTR and does not fit CAP (financing), TAR (M&A), or DIV/NAV. Given the nature of the announcement (LOI for commercial launch partnership), RNS is the most appropriate fallback.
2024-06-04 English
Observe Medical ASA announces Letter of Intent with Sulacare for Female Catheterization Product Launch
Regulatory Filings Classification · 95% confidence The document is a press release from Observe Medical ASA announcing a Letter of Intent (LOI) with Sulacare for a commercial launch partnership regarding a female catheterization product. This announcement details a strategic business development, potential future agreement terms (profit-sharing, signing by Sept 30, 2024), and contact information. It is not a formal regulatory filing like a 10-K, an earnings release (ER), or a dividend notice (DIV). It describes a potential Merger or Acquisition activity (TAR) or a general business update. Since it specifically discusses a partnership aimed at commercializing a product, which often precedes or is part of M&A strategy, but is fundamentally a strategic business development announcement, it fits best under the general category for significant corporate actions or announcements that aren't strictly financial reporting. Given the options, 'M&A Activity (TAR)' is the closest fit for a strategic partnership/collaboration announcement, although 'Regulatory Filings (RNS)' could also apply if TAR is too specific. However, the content strongly suggests a strategic business alliance/potential transaction, making TAR a strong candidate, or RNS as a general announcement. Since it is a specific announcement about a strategic collaboration/potential transaction, I will classify it as 'TAR' (M&A Activity) as these LOIs often precede formal transaction agreements, or 'RNS' as a general regulatory announcement. Given the nature of an LOI for commercialization, it is a significant corporate event announcement. I will lean towards RNS as the most appropriate general category for non-standard, non-financial press releases, as it is not a definitive M&A filing yet, but a strategic partnership announcement.
2024-06-04 English
Observe Medical provides update on strong UnoMeter[TM] momentum in UK and Irish markets
Regulatory Filings Classification · 99% confidence The document is a short press release dated June 3, 2024, providing an update on the sales momentum of the UnoMeter™ product line in the UK and Irish markets. It mentions 'Building on previous announcements' and provides contact information and a brief 'About' section. It is not a comprehensive financial report (like 10-K or IR), nor is it a transcript (CT) or a formal regulatory filing detailing insider trades (DIRS) or capital changes (CAP/SHA). Since it is a specific, non-financial operational update that doesn't fit the other specific categories (like DIV, NAV, ER, etc.), it best fits the general 'Regulatory Filings' category as a miscellaneous corporate announcement, or potentially a very brief Investor Presentation/Information piece, but given its nature as a market update announcement, RNS is the most appropriate fallback for non-standard announcements.
2024-06-03 English
Observe Medical provides update on strong UnoMeter[TM] momentum in UK and Irish markets
Regulatory Filings Classification · 95% confidence The document is a short press release dated June 3, 2024, providing an update on the sales momentum of the UnoMeterT product line in the UK and Ireland. It mentions 'Building on previous announcements' and provides contact information and a brief 'About' section. This format is characteristic of a general operational or business update, not a formal financial filing like a 10-K, IR, or ER. Since it is an announcement about business activity and momentum, and does not fit the specific categories like M&A (TAR), Dividend (DIV), or Capital Change (CAP), it falls best under the general Regulatory Filings category (RNS) as a miscellaneous regulatory announcement, or potentially an Investor Presentation (IP) if it were more strategic, but given its brevity and update nature, RNS is the most appropriate fallback for a non-standard announcement.
2024-06-03 English
Observe Medical ASA - Biim Agreement with Fresenius Medical Care Extended for 2 Years
M&A Activity Classification · 99% confidence The document is a short press release dated May 31, 2024, announcing the extension of a supply agreement between Observe Medical's subsidiary (Biim) and Fresenius Medical Care. It details a commercial partnership renewal, not a mandatory regulatory filing like a 10-K, an earnings release (ER), or a formal capital change (CAP/SHA). Since it is a specific announcement regarding business operations and commercial agreements, and it does not fit into the other specific categories (like M&A, Director's Dealing, or Dividend), the most appropriate classification is the general Regulatory Filings category (RNS), which serves as a fallback for significant, non-standard corporate announcements not covered elsewhere. Given the content is a specific business update, RNS is the best fit among the provided options.
2024-05-31 English
Observe Medical ASA - Biim Agreement with Fresenius Medical Care Extended for 2 Years
Regulatory Filings Classification · 100% confidence The document is a short press release dated May 31, 2024, announcing the extension of a supply agreement between Observe Medical's subsidiary (Biim) and Fresenius Medical Care. This announcement concerns a commercial partnership update, specifically related to the supply of medical devices. This type of announcement, which details a significant business development (contract renewal/extension) but is not a formal financial filing (like 10-K, ER, or IR), typically falls under general regulatory announcements or business updates. Since there is no specific category for 'Commercial Contract Update,' and it is not a management change (MANG), financing (CAP), or M&A (TAR), the most appropriate general category for a significant, non-financial regulatory announcement is 'Regulatory Filings' (RNS), as it serves as a catch-all for important company news released to the market that doesn't fit elsewhere. Given the short length and nature, it is not a detailed report like an Audit Report (AR) or Interim Report (IR).
2024-05-31 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.